Shoukang Group

Shoukang Group, formerly known as Regent Pacific Group, is a Hong Kong-listed healthcare and life sciences company focused on wellness and longevity. The company's flagship product is Fortacin, an EMA-approved topical spray for the treatment of premature ejaculation, which is being commercialized globally through various partnerships. Shoukang Group also maintains a significant interest in longevity science through its acquisition of Deep Longevity, a company specializing in AI-driven aging biomarkers. The group operates as a diversified healthcare entity, combining pharmaceutical commercialization with strategic investments in innovative health technologies. Its business model leverages licensing agreements to expand the market reach of its core products while exploring new frontiers in aging research.